The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms

Molecular and Cellular Endocrinology

Volumn 405, Issue , 2015, Pages 25-34

  Hwang, Hwan Jin ^a   Chung, Hye Soo ^b   Jung, Tae Woo ^a   Ryu, Ja Young ^a   Hong, Ho Cheol ^a   Seo, Ji A ^a   Kim, Sin Gon ^a   Kim, Nan Hee ^a   Choi, Kyung Mook ^a   Choi, Dong Seop ^a   Baik, Sei Hyun ^a   Yoo, Hye Jin ^a  

^a Korea University College of Medicine   (South Korea)

^b Seonam University College of Medicine   (South Korea)

Author keywords

AMP activated protein kinase; Dipeptidyl peptidase IV inhibitors; Endothelial cells; Inflammation

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GEMIGLIPTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ADENYLATE KINASE; CYTOKINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ICAM1 PROTEIN, HUMAN; INTERCELLULAR ADHESION MOLECULE 1; LC15-0444; PIPERIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANTIATHEROSCLEROTIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FOAM CELL; HUMAN; HUMAN CELL; MACROPHAGE; PROTEIN EXPRESSION; THP 1 CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; CELL ADHESION; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

ADENYLATE KINASE; CELL ADHESION; CELLS, CULTURED; CYTOKINES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; E-SELECTIN; GENE EXPRESSION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LIPOPOLYSACCHARIDES; MACROPHAGES; PIPERIDONES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; SIGNAL TRANSDUCTION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84923034778     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.01.025     Document Type: Article

References (38)

1. Arakawa M., Mita T., Azuma K., Ebato C., Goto H., Nomiyama T., et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59:1030-1037.
2. Arthur J.S., Ley S.C. Mitogen-activated protein kinases in innate immunity. Nat. Rev. Immunol 2013, 13:679-692.
3. Cacicedo J.M., Yagihashi N., Keaney J.F., Ruderman N.B., Ido Y. AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun 2004, 324:1204-1209.
4. Curtiss L.K. ApoE in atherosclerosis: a protein with multiple hats. Arterioscler. Thromb. Vasc. Biol 2000, 20:1852-1853.
5. Cybulsky M.I., Iiyama K., Li H., Zhu S., Chen M., Iiyama M., et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest 2001, 107:1255-1262.
6. Deacon C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes. Metab 2011, 13:7-18.
7. Fullerton M.D., Steinberg G.R., Schertzer J.D. Immunometabolism of AMPK in insulin resistance and atherosclerosis. Mol. Cell. Endocrinol 2013, 366:224-234.
8. Han M.S., Jung D.Y., Morel C., Lakhani S.A., Kim J.K., Flavell R.A., et al. JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science 2013, 339:218-222.
9. Hwang H.J., Jung T.W., Hong H.C., Choi H.Y., Seo J.A., Kim S.G., et al. Progranulin protects vascular endothelium against atherosclerotic inflammatory reaction via Akt/eNOS and nuclear factor-kappaB pathways. PLoS ONE 2013, 8:e76679.
10. Hwang H.J., Jung T.W., Ryu J.Y., Hong H.C., Choi H.Y., Seo J.A., et al. Dipeptidyl petidase-IV inhibitor (gemigliptin) inhibits tunicamycin-induced endoplasmic reticulum stress, apoptosis and inflammation in H9c2 cardiomyocytes. Mol. Cell. Endocrinol 2014, 392:1-7.
11. Ido Y., Carling D., Ruderman N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 2002, 51:159-167.
12. Ishibashi Y., Matsui T., Takeuchi M., Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem. Biophys. Res. Commun 2010, 391:1405-1408.
13. Kovacic S., Soltys C.L., Barr A.J., Shiojima I., Walsh K., Dyck J.R. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J. Biol. Chem 2003, 278:39422-39427.
14. Kroller-Schon S., Knorr M., Hausding M., Oelze M., Schuff A., Schell R., et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc. Res 2012, 96:140-149.
15. Legein B., Temmerman L., Biessen E.A., Lutgens E. Inflammation and immune system interactions in atherosclerosis. Cell. Mol. Life Sci 2013, 70:3847-3869.
16. Li D., Zhang Y., Ma J., Ling W., Xia M. Adenosine monophosphate activated protein kinase regulates ABCG1-mediated oxysterol efflux from endothelial cells and protects against hypercholesterolemia-induced endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol 2010, 30:1354-1362.
17. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
18. Lim S., Choi S.H., Shin H., Cho B.J., Park H.S., Ahn B.Y., et al. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PLoS ONE 2012, 7:e35007.
19. Matsubara J., Sugiyama S., Sugamura K., Nakamura T., Fujiwara Y., Akiyama E., et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J. Am. Coll. Cardiol 2012, 59:265-276.
20. Nagata D., Mogi M., Walsh K. AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J. Biol. Chem 2003, 278:31000-31006.
21. Nizamutdinova I.T., Kim Y.M., Jin H., Son K.H., Lee J.H., Chang K.C., et al. Tanshinone IIA inhibits TNF-alpha-mediated induction of VCAM-1 but not ICAM-1 through the regulation of GATA-6 and IRF-1. Int. Immunopharmacol 2012, 14:650-657.
22. Pasterkamp G., Schoneveld A.H., van der Wal A.C., Haudenschild C.C., Clarijs R.J., Becker A.E., et al. Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: the remodeling paradox. J. Am. Coll. Cardiol 1998, 32:655-662.
23. Rao R.M., Yang L., Garcia-Cardena G., Luscinskas F.W. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ. Res 2007, 101:234-247.
24. Rhee E.J., Lee W.Y., Min K.W., Shivane V.K., Sosale A.R., Jang H.C., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Obes. Metab 2013, 15:523-530.
25. Shah Z., Kampfrath T., Deiuliis J.A., Zhong J., Pineda C., Ying Z., et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011, 124:2338-2349.
26. Tsoyi K., Jang H.J., Nizamutdinova I.T., Park K., Kim Y.M., Kim H.J., et al. PTEN differentially regulates expressions of ICAM-1 and VCAM-1 through PI3K/Akt/GSK-3beta/GATA-6 signaling pathways in TNF-alpha-activated human endothelial cells. Atherosclerosis 2010, 213:115-121.
27. Ussher J.R., Drucker D.J. Cardiovascular biology of the incretin system. Endocr. Rev 2012, 33:187-215.
28. Vittone F., Liberman A., Vasic D., Ostertag R., Esser M., Walcher D., et al. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. Diabetologia 2012, 55:2267-2275.
29. Wang W.J., Chang C.H., Sun M.F., Hsu S.F., Weng C.S. DPP-4 inhibitor attenuates toxic effects of indoxyl sulfate on kidney tubular cells. PLoS ONE 2014, 9:e93447.
30. Xu Q., Si L.Y. Protective effects of AMP-activated protein kinase in the cardiovascular system. J. Cell. Mol. Med 2010, 14:2604-2613.
31. Yang Z., Kahn B.B., Shi H., Xue B.Z. Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J. Biol. Chem 2010, 285:19051-19059.
32. Yang Z.Z., Tschopp O., Baudry A., Dummler B., Hynx D., Hemmings B.A. Physiological functions of protein kinase B/Akt. Biochem. Soc. Trans 2004, 32:350-354.
33. Yazbeck R., Howarth G.S., Abbott C.A. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?. Trends Pharmacol. Sci 2009, 30:600-607.
34. Zeng Y., Li C., Guan M., Zheng Z., Li J., Xu W., et al. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms. Cardiovasc. Diabetol 2014, 13:32.
35. Zhang Y., Qiu J., Wang X., Zhang Y., Xia M. AMP-activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300. Arterioscler. Thromb. Vasc. Biol 2011, 31:2897-2908.
36. Zhang Y., Wang X., Yang H., Liu H., Lu Y., Han L., et al. Kinase AKT controls innate immune cell development and function. Immunology 2013, 140:143-152.
37. Zhong J., Rao X., Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 2013, 226:305-314.
38. Zhu Y., Liao H.L., Wang N., Friedli O., Verna L., Stemerman M.B. Low-density lipoprotein activates Jun N-terminal kinase (JNK) in human endothelial cells. Biochim. Biophys. Acta 1999, 1436:557-564.